BioWorld

Dec. 18, 2002

View Archived Issues

MedImmune's FluMist Vaccine Recommended By FDA Panel

By dropping children younger than 5 from its label, MedImmune Inc. was able to convince an FDA panel of experts that the intranasal influenza vaccine FluMist is safe and efficacious in people ages 5 to 49. (BioWorld Today Read More

Corixa's Bexxar Appears Headed For Approval After ODAC Meeting

Read More

How Botulinum's Muscle Paralysis Mechanism Combines Light, Heavy Chains In Close Molecular Embrace

Read More

Pozen Submits NDA To FDA Seeking Approval Of MT 300

Read More

Versicor Starts Phase III Trials Of Dalbavancin For Infections

Read More

Targeted Genetics Continues Cutbacks To Conserve Cash

Read More

Other News To Note

Read More